bluebird bio, Inc. (BLUE): Price and Financial Metrics
BLUE Stock Summary
- BLUE's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 16.09% of US stocks.
- Revenue growth over the past 12 months for bluebird bio Inc comes in at 461.25%, a number that bests 98.49% of the US stocks we're tracking.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for BLUE comes in at -28.96% -- higher than that of only 8.96% of stocks in our set.
- Stocks that are quantitatively similar to BLUE, based on their financial statements, market capitalization, and price volatility, are CYCN, MRKR, EVGN, KLDO, and TBPH.
- Visit BLUE's SEC page to see the company's official filings. To visit the company's web site, go to www.bluebirdbio.com.
BLUE Stock Price Chart Interactive Chart >
BLUE Price/Volume Stats
|Current price||$28.78||52-week high||$72.50|
|Prev. close||$28.12||52-week low||$24.24|
|Day high||$28.95||Avg. volume||2,153,434|
|50-day MA||$30.37||Dividend yield||N/A|
|200-day MA||$47.48||Market Cap||1.93B|
bluebird bio, Inc. (BLUE) Company Bio
Bluebird Bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies. The company was founded in 1992 and is based in Cambridge, Massachusetts.
BLUE Latest News Stream
|Loading, please wait...|
BLUE Latest Social Stream
View Full BLUE Social Stream
Latest BLUE News From Around the Web
Below are the latest news stories about bluebird bio Inc that investors may wish to consider to help them evaluate BLUE as an investment opportunity.
The decision by bluebird bio ([[BLUE]] +0.1%) to withdraw Zynteglo (betibeglogene autotemcel) for transfusion-dependent β-thalassemia (“TDT”) from the German market did not come as a surprise.A Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML) forced a temporary suspension of two clinical trials in sickle cell disease for its...
bluebird bio, Inc. (Nasdaq: BLUE) announced today business and program updates across its severe genetic disease portfolio including a revised diagnosis for the previously reported case of myelodysplastic syndrome (MDS) in its Phase 1/2 study of LentiGlobin for sickle cell disease (SCD) (bb1111), the company’s decision to withdraw ZYNTEGLO™ (betibeglogene autotemcel, beti-cel) for transfusion-dependent β-thalassemia (TDT) from the German market and a targeted reshaping of its workforce intended to enable the company to advance its late-stage gene therapy programs.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of bluebird bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 13, 2021 - BLUE
New York, New York--(Newsfile Corp. - April 13, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of bluebird bio, Inc. ("bluebird") (NASDAQ: BLUE) between May 11, 2020 and November 4, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To ...
BLUE Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds bluebird bio, Inc. Investors of Class Action and Lead Plaintiff Deadline April 13, 2021
NEW YORK, NY / ACCESSWIRE / April 13, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ:BLUE) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired bluebird securities between May 11, 2020 and November 4, 2020, both dates inclusive (the "Class Period").
BlueBird Bio, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
Investors with losses of over $100,000 are encouraged to contact the firm before April 13, 2021; click here to submit trade informationLOS ANGELES, April 13, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of BlueBird Bio, Inc. (NASDAQ: BLUE) investors that acquired shares between May 11, 2020 and November 4, 2020. Investors have until April 13, 2021 to seek an active role in this litigation. Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case. It is alleged in this complaint that Bluebird made misleading and false statements to the market. Bluebird presented insufficient data to support it...
BLUE Price Returns
Continue Researching BLUEWant to do more research on bluebird bio Inc's stock and its price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!